American Oriental Bioengineering, Inc. Makes Another Acquisition

August 10, 2007 – American Oriental Bioengineering (NYSE: AOB) will pay $40 million to buy Guangxi Boke Pharmaceutical Co. Ltd. Like American Oriental, Guangxi Boke is engaged in the business of plant-based healthcare. The privately held company produced $12 million in revenue during 2006, while American Oriental is expected to have sales of $158 million in 2007. The acqusition strategy is working well for American Oriental, which also announced much improved results for it fiscal second quarter. More details...